(Q53902861)

22 May 2018

title

The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. (English)

1 reference

22 May 2018

0 references

4

R H Belmaker

1 reference

22 May 2018

author name string

Dossenbach MRK

1

1 reference

22 May 2018

J N Beuzen

2

1 reference

22 May 2018

M Avnon

3

1 reference

22 May 2018

A Elizur

5

1 reference

22 May 2018

M Mark

6

1 reference

22 May 2018

H Munitz

7

1 reference

22 May 2018

M Schneidman

8

1 reference

22 May 2018

D Shoshani

9

1 reference

22 May 2018

P Kratky

10

1 reference

22 May 2018

S L Grundy

11

1 reference

22 May 2018

G D Tollefson

12

1 reference

22 May 2018

publication date

1 September 2000

1 reference

22 May 2018

published in

Clinical Therapeutics

1 reference

22 May 2018

volume

22

1 reference

22 May 2018

page(s)

1021-1034

1 reference

22 May 2018

issue

9

1 reference

22 May 2018

Treatment of the neuroleptic-nonresponsive schizophrenic patient

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

A report of clozapine-induced agranulocytosis in the United States. Incidence and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

Glutamate receptor dysfunction and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

Clozapine and olanzapine treatment decreases rat cortical and limbic GABA(A) receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

Mechanisms of action of atypical antipsychotic drugs: a critical analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

Olanzapine versus haloperidol treatment in first-episode psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

A rating scale for drug-induced akathisia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

Pharmacokinetics and pharmacodynamics of clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

Metabolism of clozapine by neutrophils. Possible implications for clozapine-induced agranulocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2800%2980082-X

7 January 2021

10.1016/S0149-2918(00)80082-X

Identifiers

DOI

1 reference

22 May 2018

PubMed ID

11048902

1 reference

22 May 2018